| Drug Name |
Tolbutamide |
| Drug ID |
BADD_D02240 |
| Description |
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. |
| Indications and Usage |
For treatment of NIDDM (non-insulin-dependent diabetes mellitus) in conjunction with diet and exercise. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
A10BB03; V04CA01 |
| DrugBank ID |
DB01124
|
| KEGG ID |
D00380
|
| MeSH ID |
D014044
|
| PubChem ID |
5505
|
| TTD Drug ID |
D06OIV
|
| NDC Product Code |
46438-0650; 46438-0002; 52537-003 |
| Synonyms |
Tolbutamide | Artosin | Diabetol | Diaval | Orabet | Orinase | Tolbutamid R.A.N. | Apo-Tolbutamide | Dolipol | Rastinon |
